148 related articles for article (PubMed ID: 37488446)
21. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
[TBL] [Abstract][Full Text] [Related]
22. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
24. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486
[TBL] [Abstract][Full Text] [Related]
26. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
27. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Bahleda R; Grilley-Olson JE; Govindan R; Barlesi F; Greillier L; Perol M; Ray-Coquard I; Strumberg D; Schultheis B; Dy GK; Zalcman G; Weiss GJ; Walter AO; Kornacker M; Rajagopalan P; Henderson D; Nogai H; Ocker M; Soria JC
Br J Cancer; 2017 Jun; 116(12):1505-1512. PubMed ID: 28463960
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
29. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
30. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
31. First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.
Schöffski P; Awada A; de la Bigne AM; Felloussi Z; Burbridge M; Cantero F; Colombo R; Maruzzelli S; Ammattatelli K; de Jonge M; Aftimos P; Dumez H; Sleijfer S
Eur J Cancer; 2022 Jul; 169():135-145. PubMed ID: 35567919
[TBL] [Abstract][Full Text] [Related]
32. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
[TBL] [Abstract][Full Text] [Related]
34. Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors.
Chu QS; Bouganim N; Fortier C; Zaknoen S; Stille JR; Kremer JD; Yuen E; Hui YH; de la Peña A; Lithio A; Smith PS; Batist G
Invest New Drugs; 2021 Aug; 39(4):1001-1010. PubMed ID: 33479856
[TBL] [Abstract][Full Text] [Related]
35. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
Creemers JHA; Pawlitzky I; Grosios K; Gileadi U; Middleton MR; Gerritsen WR; Mehra N; Rivoltini L; Walters I; Figdor CG; Ottevanger PB; de Vries IJM
BMJ Open; 2021 Nov; 11(11):e050725. PubMed ID: 34848513
[TBL] [Abstract][Full Text] [Related]
36. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
Falchook G; Infante J; Arkenau HT; Patel MR; Dean E; Borazanci E; Brenner A; Cook N; Lopez J; Pant S; Frankel A; Schmid P; Moore K; McCulloch W; Grimmer K; O'Farrell M; Kemble G; Burris H
EClinicalMedicine; 2021 Apr; 34():100797. PubMed ID: 33870151
[TBL] [Abstract][Full Text] [Related]
37. First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.
Keilholz U; Rohde L; Mehlitz P; Knoedler M; Schmittel A; Kümmerlen V; Klinghammer K; Treasure P; Lassus M; Steventon G; Machacek M; Utku N
Eur J Cancer; 2017 Jul; 80():14-25. PubMed ID: 28531881
[TBL] [Abstract][Full Text] [Related]
38. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
[TBL] [Abstract][Full Text] [Related]
39. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
Hong DS; Hui D; Bruera E; Janku F; Naing A; Falchook GS; Piha-Paul S; Wheler JJ; Fu S; Tsimberidou AM; Stecher M; Mohanty P; Simard J; Kurzrock R
Lancet Oncol; 2014 May; 15(6):656-66. PubMed ID: 24746841
[TBL] [Abstract][Full Text] [Related]
40. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
